Statera Biopharma (STAB), a biopharmaceutical company focused on immune therapies, Wednesday said it has agreed to enter into a strategic agreement with Coeptis Therapeutics, Inc. (COEP), to sell Statera's rights to Entolimod and other related toll-like receptor 5 (TLR5) agonists.
The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Coeptis financing.
Statera will receive a $6 million upfront payment and revenue-based milestone payments from Coeptis in exchange for Statera's rights to any product containing Entolimod as an active ingredient and all other related TLR5 agonists.
Coeptis will also assume responsibility for associated licenses, as well as Statera's interest in Genome Protection, Inc.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.